Table 2 Comparison of the risk for hypothyroidism between COP and non-COP subjects using Cox proportional hazards regression analysis.
Variable | COP subjects n = 24,328 | Non-COP subjects n = 72,984 | AHR (95% CI)* | AHRSD (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
case (%) | PY | rate | case (%) | PY | rate | |||
Overall analysis | 256 (1.1) | 118003.2 | 2.2 | 191 (0.3) | 388039.6 | 0.5 | 3.8 (3.2−4.7) | 3.5 (2.9−4.2) |
Stratified analysis | ||||||||
Age (years) | ||||||||
<20 | 13 (0.5) | 16831.6 | 0.8 | 13 (0.2) | 51829.3 | 0.3 | 2.8 (1.3−6.0) | 2.7 (1.3−5.9) |
20–34 | 87 (0.9) | 47784.4 | 1.8 | 47 (0.2) | 154037.0 | 0.3 | 4.6 (3.2−6.7) | 4.3 (3.0−6.3) |
35–49 | 101 (1.3) | 36764.0 | 2.8 | 63 (0.3) | 123190.5 | 0.5 | 4.5 (3.2−6.2) | 4.1 (3.0−5.6) |
50–64 | 36 (1.2) | 12008.6 | 3.0 | 46 (0.5) | 41774.1 | 1.1 | 2.5 (1.6−3.9) | 2.2 (1.4−3.4) |
≥65 | 19 (1.5) | 4614.5 | 4.1 | 22 (0.6) | 17208.8 | 1.3 | 3.1 (1.7−5.8) | 2.6 (1.4−4.9) |
Sex | ||||||||
Female | 216 (1.8) | 61214.7 | 3.5 | 153 (0.4) | 195917.2 | 0.8 | 3.9 (3.1−4.9) | 3.6 (2.9−4.4) |
Male | 40 (0.3) | 56788.5 | 0.7 | 38 (0.1) | 192122.5 | 0.2 | 3.2 (2.0−5.1) | 2.8 (1.8−4.4) |
Underlying comorbidity | ||||||||
Hypertension | 43 (1.5) | 10044.9 | 4.3 | 36 (0.5) | 31541.2 | 1.1 | 3.5 (2.2−5.5) | 3.0 (2.0−4.7) |
Diabetes mellitus | 28 (1.9) | 4966.4 | 5.6 | 8 (0.2) | 13774.6 | 0.6 | 9.5 (4.2−21.1) | 8.4 (3.9−18.2) |
Hyperlipidemia | 37 (1.9) | 6799.9 | 5.4 | 20 (0.4) | 20122.2 | 1.0 | 5.2 (2.9−9.2) | 4.7 (2.7−8.2) |
Rheumatoid arthritis | 5 (1.8) | 1040.6 | 4.8 | 1 (0.2) | 2403.4 | 0.4 | 8.2 (0.9−78.5) | 7.6 (0.9−66.0) |
Connective tissue disease | 4 (1.9) | 732.5 | 5.5 | 3 (0.7) | 1761.7 | 1.7 | 3.6 (0.7−18.5) | 3.2 (0.6−18.4) |
Vitiligo | 0 | — | — | 0 | — | — | — | |
Scleroderma | 0 | — | — | 0 | — | — | — | |
Psoriasis | 0 | — | — | 1 (0.2) | 2075.3 | 0.5 | — | |
Drug abuse | 15 (1.3) | 3869.2 | 3.9 | 1 (0.2) | 2534.2 | 0.4 | 5.2 (0.7−39.6) | 4.8 (0.6−36.0) |
Mental disorder | 137 (1.8) | 30038.9 | 4.6 | 35 (0.4) | 42475.6 | 0.8 | 5.5 (3.8−8.1) | 4.9 (3.4−7.1) |
Follow-up period | ||||||||
<1 month | 19 (0.1) | 1953.5 | 9.7 | 1 (<0.1) | 6052.6 | 0.2 | 41.0 (5.4−310.6) | 39.5 (5.5−285.0) |
1–6 months | 40 (0.2) | 9395.5 | 4.3 | 10 (<0.1) | 29614.6 | 0.3 | 10.5 (5.2−21.4) | 10.4 (5.2−20.9) |
7–12 months | 26 (0.1) | 10642.5 | 2.4 | 11 (<0.1) | 33938.5 | 0.3 | 6.4 (3.1−13.3) | 6.4 (3.2−12.8) |
1–2 years | 28 (0.1) | 19339.7 | 1.5 | 23 (<0.1) | 62507.6 | 0.4 | 3.1 (1.7−5.5) | 3.1 (1.9−5.0) |
2–4 years | 55 (0.3) | 30935.1 | 1.8 | 48 (0.1) | 101969.5 | 0.5 | 3.3 (2.2−4.9) | 3.3 (2.2−4.8) |
≥4 years | 88 (0.7) | 45737.0 | 1.9 | 98 (0.2) | 153957.0 | 0.6 | 2.8 (2.1−3.8) | 2.8 (2.1−3.7) |
